PharmaShots | Incisive News in 3 Shots

Subscribe Now

in-licenses

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in Non-Hodgkin's Lymphoma

Exelixis In-Licenses Second Anti-Cancer Compound from Aurigene Following the US FDA's Acceptance of IND for P-I Study of XL114 in...

October 15, 2021

Denovo In-Licenses Lundbeck's Idalopirdine for Alzheimer's Disease and Other Indications

Denovo In-Licenses Lundbeck's Idalopirdine for Alzheimer's Disease and Other Indications

July 2, 2021

Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

Novartis In-Licenses Fibroblast Activation Protein (FAP) to Expand its Oncology Radioligand Pipeline

March 31, 2021

Novartis In-Licenses BieGene's Tislelizumab to Expand its Oncology Portfolio

Novartis In-Licenses BieGene's Tislelizumab to Expand its Oncology Portfolio

January 12, 2021

Axsome In-Licenses Pfizer's Reboxetine and Esreboxetine in the US

Axsome In-Licenses Pfizer's Reboxetine and Esreboxetine in the US

January 14, 2020

Bausch Health In-Licenses Clearside's Xipere (triamcinolone acetonide suprachoroidal injectable suspension) For Macular Edema Associated with Uveitis

Bausch Health In-Licenses Clearside's Xipere (triamcinolone acetonide suprachoroidal injectable suspension) For Macular Edema Asso...

October 24, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us